Przejdź do zawartości
Merck

Role of kinin B2 receptors in opioid-induced hyperalgesia in inflammatory pain in mice.

Biological chemistry (2013-01-18)
Sébastien Grastilleur, Lionel Mouledous, Jerome Bedel, Jonathan Etcheverry, Michael Bader, Jean-Pierre Girolami, Olivier Fourcade, Bernard Frances, Vincent Minville
ABSTRAKT

Postoperative pain management is a clinical challenge that can be complicated by opioid-induced hyperalgesia (OIH). Kinin receptors could mediate both the acute and chronic phases of inflammation and pain. A few recent studies suggest that dynorphin A could maintain neuropathic pain by activating the bradykinin (BK) receptor. Thus, the effect of a single administration of sufentanil (a μ-opioid receptor agonist) was investigated in a model of carrageenan-induced inflammatory pain using three strains of mice, i.e., knockout mice for one kinin receptor, B1R or B2R (B1KO, B2KO), and wild-type C57/BL6J mice (WT) treated with either a B1R (R954) or a B2R antagonist (HOE140) or a KKS inhibitor (aprotinin). Pain was assessed and compared between the different groups using two behavioral tests exploring mechanical (von Frey filaments) and thermal (Hargreaves test) sensitivity. Pretreatment with sufentanil induced a sustained increase in pain sensitivity with a delayed return to baseline values characterizing an OIH in carrageenan-injected mice only. Sufentanil-induced OIH was not observed in B2KO but persisted in B1KO and was blunted by aprotinin and the B2R antagonist only. Collectively, our data indicate that the B2R receptor and BK synthesis or availability are essential peripheral steps in the mechanism leading to OIH in a pain context.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Supelco
Sufentanil Citrate solution, 100 μg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®
Supelco
Sufentanil-D5 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®